{
    "id": 1655,
    "fullName": "ALK T1151dup",
    "impact": "duplication",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "ALK T1151dup indicates the insertion of the duplicate amino acid, threonine (T)-1151, in the protein kinase domain of the Alk protein (UniProt.org). T1151dup has been demonstrated to occur as a secondary drug resistance mutation in the context of EML4-ALK (PMID: 22277784, PMID: 20695522), but has not been biochemically characterized and therefore, its effect on Alk protein function is unknown (PubMed, Sep 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 682,
                    "pubMedId": 20695522,
                    "title": "Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20695522"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 683,
                    "pubMedId": 22277784,
                    "title": "Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22277784"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 238,
        "geneSymbol": "ALK",
        "terms": [
            "ALK",
            "CD246",
            "NBLST3"
        ]
    },
    "variant": "T1151dup",
    "createDate": "09/10/2014",
    "updateDate": "09/29/2019",
    "referenceTranscriptCoordinates": {
        "id": 102097,
        "transcript": "NM_004304",
        "gDna": "chr2:g.29222406_29222408",
        "cDna": "c.3451_3453",
        "protein": "p.T1151",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 17758,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK T1151dup (referred to as 1151insT) in culture and in xenograft models (PMID: 24887559).",
            "molecularProfile": {
                "id": 26807,
                "profileName": "EML4 - ALK ALK T1151dup"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15763,
                    "pubMedId": 24887559,
                    "title": "Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24887559"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9264,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ALK T1151dup in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27780853).",
            "molecularProfile": {
                "id": 26807,
                "profileName": "EML4 - ALK ALK T1151dup"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7044,
                    "pubMedId": 27780853,
                    "title": "The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27780853"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12857,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ALK T1151dup in the context of EML4-ALK were resistant to Xalkori (crizotinib) in culture (PMID: 22277784).",
            "molecularProfile": {
                "id": 26807,
                "profileName": "EML4 - ALK ALK T1151dup"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 683,
                    "pubMedId": 22277784,
                    "title": "Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22277784"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9258,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ALK T1151dup in the context of EML4-ALK in culture (PMID: 27780853).",
            "molecularProfile": {
                "id": 26807,
                "profileName": "EML4 - ALK ALK T1151dup"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7044,
                    "pubMedId": 27780853,
                    "title": "The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27780853"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12793,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a non-small cell lung carcinoma patient harboring an ALK rearrangement demonstrated a partial response with Xalkori (crizotinib) treatment, but then progressed after 10.8 months, and was found to harbor secondary resistance mutations, ALK T1151dup and ALK G1269A (PMID: 25724526).",
            "molecularProfile": {
                "id": 28925,
                "profileName": "ALK rearrange ALK T1151dup ALK G1269A"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 3718,
                    "pubMedId": 25724526,
                    "title": "Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25724526"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1663,
            "profileName": "ALK T1151dup",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 10719,
            "profileName": "ALK fusion ALK T1151dup",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26807,
            "profileName": "EML4 - ALK ALK T1151dup",
            "profileTreatmentApproaches": [
                {
                    "id": 16828,
                    "name": "Brigatinib",
                    "profileName": "EML4 - ALK ALK T1151dup"
                }
            ]
        },
        {
            "id": 28925,
            "profileName": "ALK rearrange ALK T1151dup ALK G1269A",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 102097,
            "transcript": "NM_004304",
            "gDna": "chr2:g.29222406_29222408",
            "cDna": "c.3451_3453",
            "protein": "p.T1151",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}